JNJ · News · 20261020N

Revenue Performance and Mix

JOHNSON & JOHNSON · 2026-10-20 · Importance 32 · Surprise 24

Johnson & Johnson reported a third-quarter 2026 earnings beat on both revenue and earnings, but its MedTech segment fell short of market expectations. Management cited geopolitical headwinds from the Middle East conflict and pricing pressure in China as ongoing risks to performance. The company modestly raised its full-year 2026 revenue and earnings guidance after the quarterly results. Broader declines in cardiovascular and surgery divisions partly offset strong global Shockwave sales.

Key facts

• Johnson & Johnson reported long term Phase 3 and extension trial data for TREMFYA and ICOTYDE in Crohn's disease and plaque psoriasis. source
• Johnson & Johnson's shares have surged 22.4% year to date, outpacing the S&P 500's 12.1% gain. source
• Capital Group Core Balanced ETF made its largest purchase a new stake in Johnson & Johnson of $35.7M on Oct. 16, buying 139,612 shares. source
• Johnson & Johnson's MedTech segment fell short of expectations for Q3 2026, contributing to the initial stock decline after earnings. source
• Johnson & Johnson's second-quarter 2026 GAAP EPS was $2.27, versus $2.90 after excluding intangible amortization and special items, including litigation and separation costs. source
• Shares of Johnson & Johnson initially dropped nearly 6% on Oct. 13 after announcing third-quarter 2026 results despite beating Wall Street estimates on both the top and bottom lines. source
• Johnson & Johnson's forward P/E is approximately 21x and trailing P/E is 31x as reported in the article. source